Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Plasmablastic Lymphoma: early-phase trial registry
3 of 4 indexed Plasmablastic Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Plasmablastic Lymphoma: 4 US clinical trials tracked, 3 recruiting.
Plasmablastic Lymphoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is AIDS Malignancy Consortium, running 3 of these trials.
Enrollment posture brief
Registry condition plasmablastic-lymphoma
OPEN 3 | RECR 75% | LATE 0 | EARLY 3 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Plasmablastic Lymphoma lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Plasmablastic Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Plasmablastic Lymphoma is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
AIDS Malignancy Consortium
NCT05663502
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Cancer Institute (NCI)
NCT05389423
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
AIDS Malignancy Consortium
NCT04139304
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
AIDS Malignancy Consortium
NCT02797470
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Plasmablastic Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Plasmablastic Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Plasmablastic Lymphoma page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Plasmablastic Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AIDS Malignancy Consortium sponsors the most Plasmablastic Lymphoma trials on record, review their full trial history before evaluating a specific study. See AIDS Malignancy Consortium's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Plasmablastic Lymphoma condition card totals 4 registered trials; most-linked intervention Etoposide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.